Tag Archives: Novartis
By Pharm Exec | Published: June 13, 2014
The future of GSK’s Tykerb (lapatinib) in the breast cancer market is unclear, after the combination of Tykerb and Herceptin in the large Phase III trial, ALTTO, showed no statistical superiority over Herceptin alone for improving disease-free survival, says research and consulting firm GlobalData.
By William Looney | Published: June 10, 2014
Therapeutic specialization, competitive differentiation, and a finely-tailored value proposition are creating a new drug world of bespoke market niches—and infinite future possibilities for the best of this year’s Pharma 50. The vigorous return of M&A activity to biopharmaceuticals this year brings us back to the question that industry strategists have been posing for years: is […]
By Pharm Exec | Published: May 13, 2014
Novartis has teamed with the French drug maker Servier to develop and commercialize novel drug candidates targeting apoptosis in oncology.
By Julian Upton | Published: April 22, 2014
What’s the opposite of Black Tuesday? White Tuesday? Bright Tuesday? Because Tuesday the stock market was buzzing following the news that Novartis is to acquire GSK’s cancer drugs business, while selling its vaccines division to GSK. With the speculation of a $100bn Pfizer bid for AstraZeneca and Valeant Pharmaceuticals added in, prices went soaring. As of […]
By Ben Comer | Published: January 17, 2014
Presenters at the 32nd annual J.P. Morgan Healthcare Conference talked up value-based pricing, emerging market strategies, complex generics and new technology, from bedside devices and genetic sequencers to first-in-class mechanisms of action. Company executives honed in on their chosen therapeutic areas and made the case for aggressive spending in R&D to bring the next generation […]